CTS-21166
CTS-21166 Uses, Dosage, Side Effects, Food Interaction and all others data.
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and oral availability; all of these have met the requirements of an ideal oral drug candidate.
CTS-21166 produced a rapid and significant reduction of plasma amyloid beta, a key biomarker that is believed to be involved in the pathogenesis of Alzheimer's disease. CTS-21166 demonstrated excellent pharmacokinetic properties including dose proportional exposure and very low inter-subject pharmacokinetic variability.
| Trade Name | CTS-21166 |
| Generic | CTS-21166 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in alzheimer's disease.
How CTS-21166 works
Beta secretase is the enzyme thought responsible for causing Alzheimer’s. CTS-21166 is a highly selective, potent and orally active beta-secretase inhibitor.
Innovators Monograph
You find simplified version here CTS-21166
